Phase 2 trial results, published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023), demonstrated that participants receiving the highest dose of retatrutide lost an average of approximately 24% of their body weight over 48 weeks a finding that attracted considerable attention from the medical and scientific communities
NHS access began in specialist weight management services from June 2025 for the highest-need patients, with tirzepatide prescribing incorporated into the GP Quality and Outcomes Framework from April 2026
What is still being studied Open scientific questions Long-term safety beyond the trial duration, weight regain after discontinuation, comparative effectiveness against Tirzepatide head-to-head, and response variability across populations are all areas where evidence is still maturing
The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell surface expression
Scientists are now investigating GLP-1s potential effectiveness against alcohol use disorder, opioid addiction, and nicotine dependence
We offer pickup, drive-thru service, or direct shipping
